secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortrea Holdings Inc. (FTRE)
CIK:        0001965040
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001965040-24-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortrea reports Q4 book-to-bill >1.2x; exits 40% of TSAs; review clears trial conduct
--------------------------------------------------------------------------------

- Book-to-bill ratio exceeded 1.2x for Q4 2023 and for first six months as an independent company.
- Exited approximately 40% of Transition Services Agreements with former parent by end of 2023.
- Hired a recognized AI industry expert to lead machine learning efforts.
- Independent expert review found no deficit in Fortrea's conduct on two ACELYRIN clinical trials.
- Select new business proposals and awards were affected by news surrounding the clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1965040/000196504024000002/0001965040-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1965040/000196504024000002/ftre-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001965040-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer